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Activation of NF-E2–Related Factor-2 Reverses
Biochemical Dysfunction of Endothelial Cells Induced by
Hyperglycemia Linked to Vascular Disease
Mingzhan Xue,1 Qingwen Qian,2 Antonysunil Adaikalakoteswari,1 Naila Rabbani,1,2
Roya Babaei-Jadidi,2 and Paul J. Thornalley1,2
OBJECTIVE—Sulforaphane is an activator of transcription factor
NF-E2–related factor-2 (nrf2) that regulates gene expression
through the promoter antioxidant response element (ARE). Nrf2
regulates the transcription of a battery of protective and metabolic
enzymes. The aim of this study was to assess whether activation of
nrf2 by sulforaphane in human microvascular endothelial cells
prevents metabolic dysfunction in hyperglycemia.
RESEARCH DESIGN AND METHODS—Human microvascu-
lar HMEC-1 endothelial cells were incubated in low and high
glucose concentrations (5 and 30 mmol/l, respectively), and
activation of nrf2 was assessed by nuclear translocation. The
effects of sulforaphane on multiple pathways of biochemical
dysfunction, increased reactive oxygen species (ROS) formation,
hexosamine pathway, protein kinase C (PKC) pathway, and
increased formation of methylglyoxal were assessed.
RESULTS—Activation of nrf2 by sulforaphane induced nuclear
translocation of nrf2 and increased ARE-linked gene expression, for
example, three- to fivefold increased expression of transketolase
and glutathione reductase. Hyperglycemia increased the formation
of ROS—an effect linked to mitochondrial dysfunction and pre-
vented by sulforaphane. ROS formation was increased further by
knockdown of nrf2 and transketolase expression. This also abol-
ished the counteracting effect of sulforaphane, suggesting mediation
by nrf2 and related increase of transketolase expression. Sulfora-
phane also prevented hyperglycemia-induced activation of the hex-
osamine and PKC pathways and prevented increased cellular
accumulation and excretion of the glycating agent methylglyoxal.
CONCLUSIONS—We conclude that activation of nrf2 may prevent
biochemical dysfunction and related functional responses of endothe-
lial cells induced by hyperglycemia in which increased expression of
transketolase has a pivotal role. Diabetes 57:2809–2817, 2008
There is an increased risk of vascular disease indiabetes that is a major cause of patient morbid-ity and mortality. This gives rise to a character-istic spectrum of diabetic microvascular disease
(retinopathy, nephropathy, and neuropathy) and macro-
vascular disease (heart disease and stroke) (1–4). Vascu-
lar disease in diabetes is associated with dysfunction of
endothelial cells in hyperglycemia. Activation of multiple
pathways of biochemical dysfunction induced in vascular
endothelial cells by high glucose concentration is thought
to underlie the link of hyperglycemia in diabetes to the
development of vascular disease (5,6). A common feature
of endothelial cell dysfunction in hyperglycemia is in-
creased formation of reactive oxygen species (ROS) by
mitochondria, oxidative stress with inactivation of glycer-
aldehyde-3-phosphate dehydrogenase, and accumulation
of triosephosphates and fructose-6-phosphate (7–9). There
is an associated activation of protein kinase C (PKC),
hexosamine pathway O-linked protein glycosylation, and
increased glycation by methylglyoxal and other dicarbon-
yls forming advanced glycation end products (10–12). This
appears to be driven mainly by the accumulation of
glycolytic intermediates. Recent research has indicated
that activation of the reduced pentosephosphate path-
way by high-dose thiamine and related prodrug benfo-
tiamine may counter this metabolic dysfunction (9,13,14),
but little is known of the endogenous coordinated stress
response to decrease triosephosphate accumulation and
its link to increased ROS formation and oxidative stress in
hyperglycemia.
NF-E2–related factor-2 (nrf2) is a member of the cap ‘n’
collar subfamily of bZIP transcription factors. It is an
essential transactivator of genes containing an antioxidant
response element (ARE) in their promoter (rev. in 15,16).
ARE-linked genes include a battery of protective and
metabolic enzymes: -glutamylcysteine ligase, glutathione
reductase (GSHRd), aldo-keto reductase (AKRd), glutathi-
one transferases, quinone reductase (NQO1), nrf2 (17),
and others (18). Nrf2-linked gene expression has a key role
in the protection of cells against oxidative stress, carbonyl
compounds, and electrophilic agents. Interestingly, the
thiamine-dependent enzyme transketolase and transaldo-
lase are also ARE-linked genes (18). Transketolase is
considered to be the rate-controlling enzyme in the pen-
tosephosphate pathway.
Under basal conditions, nrf2 is complexed with Kelch-
like ECH-associated protein 1 (Keap1), a BTB-Kelch pro-
tein. Keap1 is a substrate adaptor protein for a Cul
3–dependent E3 ubiquitin ligase complex, directing nrf2
for proteasomal degradation (19). Oxidative stress, elect-
rophiles, and sulforaphane-like inducers disrupt the
Keap1-nrf2 complex: nrf2 translocates to the nucleus and,
combining with small maf protein (20), induces ARE-
linked gene expression (21). Sulforaphane releases nrf2
from Keap1 by modification of critical cysteine thiol
residues (22). Keap1 has concurrent increased susceptibil-
ity to degradation but also has ARE-linked gene expres-
sion and may be induced by nrf2 activation, providing an
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autoregulatory feedback loop (23). Nrf2 also undergoes
nuclear export, establishing cytoplasmic/nuclear dynamic
shuttling (24). Recent research has suggested that the
serine/threonine kinase CK2 has a role in nuclear import of
nrf2 and that both CK2 and tyrosine kinase Fyn influence
nuclear export and degradation of nrf2 (25,26) (Fig. 1A).
There is an active nrf2–Keap-1 system in vascular endo-
thelial cells (27).
The role, if any, of nrf2-linked gene expression in
countering endothelial dysfunction in hyperglycemia has
not been disclosed. Disposal of glyceraldehyde-3-phos-
phate and fructose-6-phosphate by the reductive pentose-
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FIG. 1. Nrf2 activation and transketolase expression in human HMEC-1 endothelial cells in vitro. A: Schematic diagram showing activation of nrf2
and dynamic nuclear-cytoplasmic shuttling of nrf2 for ARE-linked expression. B: Multiple pathways of biochemical dysfunction induced by
hyperglycemia in microvascular endothelial cells and effect of nrf2 activated, ARE-mediated induction of transketolase expression. Other
mechanisms of biochemical dysfunction may be involved.
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phosphate pathway induced by activation of nrf2 and
increased expression of transketolase suggested a possi-
ble mechanism of intervention. In this report, we show
that activation of nrf2 by the dietary activator sulfora-
phane, limited to concentration ranges found in plasma
after consumption of broccoli (28) for relevance to future
clinical dietary intervention, increased the expression of
protective enzymes under ARE-linked transcriptional con-
trol and prevented metabolic dysfunction in endothelial
cells induced by hyperglycemia in which increased expres-
sion of transketolase has a critical role.
RESEARCH DESIGN AND METHODS
Reagents. MCDB-131 medium, FCS, Alexa Fluor 488 rabbit anti-mouse IgG
and 2,7-dichlorodihydrofluorescein diacetate (H2DCFDA) were purchased
from Invitrogen (Paisley, U.K.). Monoclonal (mouse) anti–O-linked N-acetyl-
glucosamine (Clone RL2) was purchased from Abcam (Cambridge, U.K.). All
other chemicals were obtained from Sigma-Aldrich (Poole, Dorset, U.K.),
unless otherwise stated.
Cell culture. Human microvascular HMEC-1 endothelial cells were cultured
as described previously (29). HMEC-1 cells (4–6  106) were incubated in
MCDB-131 medium with 10% serum, 10 mmol/l L-glutamine, 10 ng/ml epider-
mal growth factor, and 1 g/ml hydrocortisone in 92-mm-diameter Petri dishes
with low glucose (5 mmol/l) and high glucose (30 mmol/l) in the absence and
presence of 4 mol/l sulforaphane for 6–48 h, trypsinized, and analyzed as
described below.
Small interfering RNA transfection. HMEC-1 endothelial cells were incu-
bated in MCDB-131 medium with 10% serum and then transfected with small
interfering RNA (siRNA) for nrf2 (SI00657030; Qiagen) or transketolase
(SI02653791) using the HiPerfect transfection reagent according to the man-
ufacturer’s instructions. The incubation was then continued with normal
medium for 24 h. Cultures were then continued with low and high glucose
concentrations in the absence and presence of 4 mol/l sulforaphane for 6 or
24 h and/or other additives. Knockdown was confirmed by real-time RT-PCR
for nrf2 and transketolase. RNA was extracted using the RNeasy minikit
(Qiagen), reverse transcribed by SuperScript III First Strand Synthesis system
(Invitrogen), and quantified by real-time RT-PCR using the TaqMan MGB
probes, designed and supplied by Applied Biosystems. Knockdown was 60%
for transketolase and 90% for nrf2.
Nuclear translocation of nrf2 by immunoblotting. Nuclear and cytosolic
proteins were isolated from HMEC-1 cells incubated with and without
sulforaphane using a CelLytic NuCLEAR extraction kit (Sigma). Trypsinized
cells were washed in PBS at 4°C, and the cell pellet was lysed with hypotonic
lysate buffer containing dithiothreitol, a protease inhibitor cocktail, and
IGEPAL CA-630 on ice for 15 min. The lysate was centrifuged (11,000 g, 30 s,
4°C), and the supernatant was used for the cytosolic extract. The pellet (crude
nuclear fraction) was treated with extraction buffer containing dithiothreitol
and protease inhibitor cocktail at 4°C for 30 min, vortex mixed, and centri-
fuged (21,000  g, 4°C, 5 min). The supernatant was collected for the nuclear
extract. All protein extracts were frozen at 80°C immediately until further
analysis. The protein concentration was determined with EZQ Protein Quan-
titation kit (Invitrogen).
Proteins in the cytosolic and nuclear fractions were separated by 10%
SDS-PAGE and transferred electrophoretically onto polyvinylidene difluoride
membrane, and the membrane was blocked with 5% nonfat milk in Tris-
buffered saline–Tween buffer (10 mmol/l Tris-HCl, pH 7.5; 150 mmol/l NaCl;
and 0.05% Tween-20). The membrane was probed with anti-nrf2 antibody
(H-300; 1:1,500 dilution) overnight at 4°C. After washing, the membrane was
incubated with horseradish peroxidase–conjugated second antibody (1:3,000
diluted; Sigma) for 1 h at room temperature, and immunoconjugate was
detected with enhanced chemiluminescence. The membrane was then incu-
bated with stripping buffer (100 mmol/l -mercaptoethanol, 2% SDS, and 62.5
mmol/l Tris-HCl, pH 6.8), blocked with 5% nonfat milk in Tris-buffered
saline–Tween buffer, and reprobed with antibodies to reference proteins
-actin and lamin A. Protein band intensities were quantified using Image-
Quant TL software (Amersham Biosciences).
Characterization of biochemical dysfunction. The intracellular formation
of ROS was detected using the fluorogenic probe H2DCFDA. Cells (2  10
6)
were incubated with and without sulforaphane and mitochondrial inhibitors
for 24 h, washed with PBS, and then incubated further with 20 mol/l
H2DCFDA for 45 min, washed again, and analyzed by flow cytometry. Shorter
incubations of 1-h preincubation in hyperglycemia with and without mito-
chondrial inhibitors were also performed by microplate fluorescence mea-
surements, normalizing the fluorescence intensity to cell number. The effect of
treatments on cell viability was assessed by Trypan blue exclusion.
Hexosamine pathway activity was assessed by a quantitative dot Western
blot assay for O-linked N-acetylglucosamine modified protein. Cytosolic
protein extracts (0.7 g in 5 l PBS) were immunoblotted with RL2 antibody
(1:800 dilution in blocking buffer) for 3 h at room temperature, blocked with
10% BSA, and washed (30). The immunocomplexes were detected with Alexa
Fluor 488 rabbit anti-mouse IgG (1:700 dilution) and quantified by microplate
fluorimetry. The concentrations of methylglyoxal in HMEC-1 cells and me-
dium of cultures with and without sulforaphane were determined by deriva-
tization with 1,2-diaminobenzene and quantitation by liquid chromatography
with tandem mass spectrometric detection and stable isotopic dilution
analysis (12). PKC activity was assayed in membrane and particulate fractions
of HMEC-1 cells with exogenous diacylglycerol (1,2-dioleoyl-sn-glycerol;
DAG) activator and epidermal growth factor receptor peptide fragment
VRKRTLRRL as substrate (9).
Statistical analyses. All statistical analyses were performed using paired
Student’s t test, and results are expressed as means SD. A P value	0.05 was
considered to be significant.
RESULTS
Activation of nrf2 and ARE-linked gene expression in
endothelial cells by the dietary activator sulfora-
phane. We investigated the activation status of nrf2 in
human microvascular endothelial cells by assessing nu-
clear translocation of human nrf2 by immunoblotting in
cytosolic and nuclear fractions and confocal microscopy
of nrf2-GFP fusion protein. HMEC-1 endothelial cells
incubated in model hyperglycemia (30 mmol/l glucose)
showed no significant nuclear translocation of nrf2 with
respect to normoglycemic control (5 mmol/l glucose) after
incubation for 6 h. Addition of 4 mol/l sulforaphane gave
a twofold increase in nuclear nrf2 in both normoglycemic
and hyperglycemic cultures. In the normoglycemic cul-
ture, the concentration of nrf2 in the cytosol was de-
creased concomitantly; whereas in the hyperglycemic
culture, the concentration of nrf2 in the cytosol was
increased. This suggests that the double insult of hyper-
glycemia and sulforaphane increased the cellular content
of nrf2 protein (Fig. 2A and B). This concentration of
sulforaphane did not induce significant cytotoxicity in
HMEC-1 cells in incubations for up to 48 h, as assessed in
previous studies (31). Transketolase activity of HMEC-1
cells was determined spectrophotometrically, as we have
previously described (9).
Real-time RT-PCR analysis of target ARE-linked gene
expression revealed a marked fivefold induction of transke-
tolase mRNA in cells stimulated with sulforaphane (Fig. 3A)
and a lower, three- to fourfold increase in GSHRd mRNA
(Fig. 3B). The cytosolic activity of transketolase was in-
creased 40–60% by exposure to sulforaphane (Fig. 3C). The
increase in expression of transketolase induced by sulfora-
phane in normoglycemic and hyperglycemic cultures was
prevented by knockdown of nrf2 expression (Fig. 3A). To
confirm that there is an ARE-linked induction of gene expres-
sion by sulforaphane in HMEC-1 cells, we studied the mRNA
levels of the typical nrf2-linked, ARE-mediated gene, NQO1.
NQO1 expression, normalized to culture in normoglycemia,
was increased approximately twofold in HMEC-1 cells incu-
bated with 4 mol/l sulforaphane in normoglycemic and
hyperglycemic conditions. Basal and sulforaphane-induced
expression of NQO1 in hyperglycemic culture was decreased
56 and 31%, respectively, by knockdown of nrf2 with siRNA
(Fig. 3D).
Increased formation of ROS by endothelial cells in
hyperglycemia, reversal by sulforaphane, and critical
role of transketolase. To examine the effect of ARE-
linked gene expression on biochemical dysfunction in
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hyperglycemia, the cellular production of ROS was quan-
tified. Hyperglycemic culture of endothelial cells produced
a threefold increased formation of ROS (Fig. 4A). This was
not induced by the addition of 25 mmol/l L-glucose (which
does not permeate into endothelial cells) to the normogly-
cemic control. Incubation of endothelial cells with sulfora-
phane reversed the increase in ROS by 73%, suggesting
that activation of ARE-linked gene expression prevented
increased ROS formation. Increased ROS formation by
HMEC-1 cells in hyperglycemic cultures was prevented by
incubation for 60 min with mitochondrial inhibitors (ROS
formation [percentage of normoglycemic control]: 10
mol/l p-trifluoromethoxycarbonylcyanide phenylhydra-
zone, 94  3%; 5 mol/l rotenone, 104  3%; and 2 mol/l
myxothiazole, 88  3%). This suggests that dysfunction of
mitochondria was a primary source of the increased ROS
and electron flux, although complexes I and III contrib-
uted to this effect. Incubation of HMEC-1 cells with these
inhibitors for 24 h decreased cell viability by 40–50% and
masked the effect of rotenone.
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FIG. 2. Nuclear translocation of nrf2 in human HMEC-1 endothelial cells in vitro activated by sulforaphane. Nuclear fraction (A) and cytosolic
fraction (B) immunoblotting for nrf2 (98-kDa band). Densitometric intensity ratios are means  SD (n  3). N, 5 mmol/l glucose; H, 30 mmol/l
glucose; NSFN, 5 mmol/l glucose  4 mol/l sulforaphane; and HSFN, 30 mmol/l glucose  4 mol/l sulforaphane. *P < 0.05, **P < 0.01, and
***P < 0.001 with respect to N; EP < 0.05 and EEP < 0.01 with respect to H.
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We next sought evidence of whether the prevention of
increased formation of ROS was dependent on nrf2. We
transfected endothelial cells with siRNA to knockdown ex-
pression of nrf2 and confirmed this by PCR and real-time
RT-PCR (Fig. 4B). Decreasing the expression of nrf2 exacer-
bated ROS production in both normoglycemic and hypergly-
cemic cultures; ROS was increased 145% with 5 mmol/l
glucose and 190% with 30 mmol/l glucose, with respect to
cells with 5 and 30 mmol/l glucose transfected with scram-
bled siRNA. The increased formation of ROS with nrf2
knockdown was maintained and not reversed by sulfora-
phane, which is consistent with the prevention of increased
ROS by sulforaphane being mediated by activation of nrf2
rather than a direct antioxidant effect of sulforaphane.
Knockdown of transketolase by transfection of endothelial
cells with siRNA also exacerbated ROS production in both
normoglycemic and hyperglycemic cultures: ROS was in-
creased 247 and 131%, respectively, with respect to cultures
with 5 and 30 mmol/l glucose transfected with scrambled
siRNA. The increased formation of ROS with transketolase
siRNA knockdown was maintained and not reversed by
sulforaphane, consistent with the prevention of increased
ROS by sulforaphane being mediated by increased expres-
sion of transketolase (Fig. 4B).
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FIG. 3. Effect of sulforaphane on ARE-linked gene expression in HMEC-1 endothelial cells in hyperglycemic culture in vitro. A: Effect of
hyperglycemia and sulforaphane on expression of transketolase, with and without knockdown of nrf2. B: Effect of hyperglycemia and
sulforaphane on expression of GSHRd. C: Transketolase activity of HMEC-1 cells; effect of hyperglycemia and sulforaphane. D: Effect of
hyperglycemia and sulforaphane on expression of NQO1. Transketolase, GSHRd, and NQO1 mRNA were quantified by real-time RT-PCR;
AN(nrf2), transfection for nrf2 knockdown. Data are means  SD (n  3, except n  6 for transketolase activity). *P < 0.05, **P < 0.01, and
***P < 0.001 with respect to N; EEP < 0.01 with respect to H.
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Multiple pathways of biochemical dysfunction in en-
dothelial cells in hyperglycemia and reversal by sul-
foraphane. Reversal of increased mitochondrial ROS
formation is expected to counter biochemical dysfunction
in multiple pathways. Hyperglycemia increased the activ-
ity of PKC by 180% in the cytosolic fraction and by 347% in
the membrane fraction of HMEC-1 endothelial cells. These
increases were reversed partially in both cytosolic and
membrane fractions by sulforaphane: The hyperglycemia-
induced increase in PKC activity was reversed 40% in the
cytosolic fraction and 67% in the membrane fraction (Fig.
5A and B). Similarly, hexosamine pathway–activated en-
zymatic O-linked glycosylation increased twofold in hyper-
glycemia and was reversed by sulforaphane (Fig. 5C).
Finally, the concentrations of methylglyoxal in HMEC-1
cells and medium was increased twofold in hyperglycemia
and reversed by sulforaphane (Fig. 5D).
DISCUSSION
The reversal of biochemical dysfunction of endothelial
cells in hyperglycemia by sulforaphane suggests that acti-
vation of nrf2 and related ARE-linked gene expression is a
novel strategy to suppress endothelial cell dysfunction and
possibly also the development of vascular disease in
diabetes. For example, decreased cellular and extracellu-
lar secretion of methylglyoxal is expected to prevent
dicarbonyl glycation of cellular and extracellular matrix
proteins and to prevent hyperglycemia-induced endothe-
lial cell detachment and anoikis (12). Similarly increased
ARE-linked gene expression in human aortal endothelial
cells engineered by adenovirus-mediated expression of
Nrf2 protected human aortal endothelial cells from cyto-
toxicity induced by hydrogen peroxide and tumor necrosis
factor-
–induced increased expression of monocyte che-
moattractant protein-1 and vascular adhesion molecule-1.
This suggests that increased activation of nrf2 may also
confer antiatherogenic activity (32).
Activation of nrf2 by sulforaphane produced nuclear
accumulation of the 98-kDa band of nrf2 protein. The
98-kDa band has ARE binding activity and is produced
by kinase CK2-catalyzed phosphorylation. Nrf2 levels in
cells are regulated by further phosphorylation, nuclear
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FIG. 4. Biochemical dysfunction in HMEC-1 endothelial cells in hyperglycemic culture and reversal by sulforaphane in vitro: ROS formation. A and
B: Assessment of cellular ROS formation. H(L), 5 mmol/l D()-glucose with 25 mmol/l L()-glucose; AN(nrf2), transfection with siRNA for nrf2
knockdown; AN(TK), transfection with siRNA for transketolase knockdown; and AN(scr), transfection with scrambled sequence siRNA. Data are
means  SD (n  3). * and ESignificance with respect to normoglycemic (N) and hyperglycemic (H) control, respectively, with 1, 2, and 3 symbols
representing P < 0.05, 0.01, and 0.001, respectively.
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export, and degradation, which may be enhanced by
ARE-linked expression of Keap1 (23,26,33). Nrf2 may
also exhibit ARE-linked expression. Quantitative West-
ern blotting for nrf2 revealed increased nrf2 in both the
nucleus and cytosol in hyperglycemia with sulforaphane
treatment, suggesting that total cellular nrf2 protein had
increased but only with costimulation from both sul-
foraphane and hyperglycemia. The expression of nrf2 is
ARE-regulated with nrf2 binding to its own promoter
(17). Hyperglycemia may synergize with sulforaphane
to increase nrf2 via ARE-induced expression by in-
creasing endogenous activators of nrf2, such as 4-
hydroxynonenal (34), increasing the activity of CK2
via Ca2/calmodulin-dependent mechanisms (25,35) or
other activatory mechanism. This may reflect an ARE-
linked, antistress response to hyperglycemia in endothe-
lial cells, albeit too weak to mount an adequate defense
against the metabolic insult.
Although nrf2 activation leads to increased expression
of enzymes linked to antioxidant functions countering
oxidative stress, in this study, increased expression of
transketolase made a critical and pivotal intervention. The
increased reductive pentosephosphate pathway activity
thereby achieved counters the accumulation of triosephos-
phates and fructose-6-phosphate driving metabolic dys-
function (9). The protective role of the reductive
pentosephosphate pathway in ARE-linked gene expression
has hitherto not been identified, although increased tran-
sketolase expression is associated with the dietary restric-
tion model of healthy ageing (36). Enzymatic activity of
transketolase in the pentosephosphate pathway produces
indirectly the NADPH cofactor for other ARE-linked gene
products, GSHRd, AKRd, NQO1, and thioredoxin reduc-
tase, that contribute to countering the effects of oxidative
stress (37). Therefore, contributions of other ARE-linked
gene expression in synergism with transketolase in rever-
sal metabolic dysfunction in hyperglycemia cannot be
excluded.
Multiple pathways of biochemical dysfunction in
HMEC-1 cells induced by hyperglycemia were reversed by
sulforaphane, except reversal of PKC activation was resis-
tant to the response. This may be due to ARE-linked
induced expression of 1-acylglycerol-3-phosphate O-acyl-
transferase 3 by sulforaphane (38). This enzyme converts
lysophosphatidic acid to phosphatidic acid, a precursor of
the PKC activator DAG in de novo synthesis stimulated in
hyperglycemia. The increased expression of this ARE-
linked gene may maintain increased levels of DAG,
although the increased concentrations of glycolytic inter-
mediates upstream driving de novo synthesis of DAG are
expected to have been corrected. Prolonged exposure to
increased levels of DAG has been suggested as a stimulus
of increased PKC expression in hyperglycemia associated
with diabetes that may underlie the increased specific
activity of PKC in both membrane and cytosolic cell
fractions found herein. Alternatively, when we studied
activation of transketolase by high-dose thiamine supple-
ments (7), we also found an incomplete reversal of hyper-
glycemia-induced increase in PKC activity. This may
suggest that factors other than those influenced by tran-
sketolase contribute to PKC activation in hyperglycemia.
The prevention of nrf2 activation by sulforaphane by
addition of GSH may be interpreted as an effect of GSH
acting as an antioxidant. However, sulforaphane and other
isothiocyanates bind reversibly to nonprotein thiols, such
as GSH, decreasing the concentration of free sulforaphane
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FIG. 5. Biochemical dysfunction in HMEC-1 endothelial cells in hyperglycemic culture and reversal by sulforaphane in vitro. A and B: Cytosolic
and membrane PKC activity, respectively. C: O-linked protein glycosylation of cell protein extracts. D: Effect on methylglyoxal concentrations:
concentration in culture medium (f) and cellular content (). Data are means SD (n 3). *P< 0.05, **P< 0.01, and ***P< 0.001 with respect
to N; EEP < 0.01 and EEEP < 0.001 with respect to H.
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available to modify Keap1. The residual low concentration
of free sulforaphane is inadequate to produce a pharma-
cological response and undergoes slow inactivation by
spontaneous hydrolysis (39). The inhibition of nrf2 activa-
tion by GSH may, therefore, also reflect interception of
sulforaphane in the extracellular medium and prevention
of it reaching the cellular receptors, such as Keap1.
Sulforaphane and related isothiocyanates are cytotoxic
to endothelial cells and other cells at higher concentra-
tions than used herein (typically 20–40 mol/l) (31,40).
The cytotoxicity is mediated through interactions with
death receptors and apoptotic signaling (41), also involv-
ing inhibition of p38 mitogen-activated protein kinase (42),
mitogen-activated protein kinase kinase kinase-1 (43),
and protein phosphatase M3/6 (44), and activation of
extracellular signal–related kinase 1/2 and Jun NH2-
terminal kinase (45). This is independent of the disruption
of the Keap1-nrf2 complex. Such concentrations of sul-
foraphane are higher than achieved by Brassica spp.
vegetable consumption (28), and related cell signaling is
expected to be of limited relevance to dietary exposures of
sulforaphane.
There was increased formation of ROS by HMEC-1 cells
in model hyperglycemia of 30 mmol/l D-glucose. The lack
of similar effect induced by L-glucose indicated that glu-
cose entry and metabolism into cells was required for
increased ROS formation. Increased ROS formation was
linked to mitochondrial dysfunction, consistent with pre-
vious reports (10), in which complexes I and III were
involved—the former probably by reverse electron flow
from complex II (46). Incubation of HMEC-1 cells with the
mitochondrial inhibitors for 24 h produced significant
cytotoxicity and masked the role of complex I in hyper-
glycemia-induced ROS formation. Incubation with inhibi-
tors for 1 h did not induce cytotoxicity. Similar effects may
have compromised the outcome of previous studies of this
type (47). Other sources of increased ROS formation in
microvascular endothelial cells in hyperglycemia have
been identified: activation of vascular NADPH oxidase;
inactivation and uncoupling of endothelial nitric oxide
synthase (48,49); and related upstream signaling linked to
poly(ADP-ribose) polymerase (PARP) (7), aldose reduc-
tase (50), and the xanthine/xanthine oxidase system (51).
Mitochondrial metabolism appears to be a major site of
ROS formation in the HMEC-1 cell culture model. There
are interrelated mechanisms, however, that may explain
how sulforaphane-induced ARE-linked gene expression
could prevent activation of other pathways. Activation of
PARP may be prevented by sulforaphane-induced in-
creased expression of antioxidant enzymes, preventing
oxidative damage to DNA. The activation of the polyol
pathway may be prevented by sulforaphane decreasing the
cellular concentration of methylglyoxal and thereby pre-
venting methylglyoxal-induced expression of aldose re-
ductase (52).
These findings provide the biochemical basis for the link
of a vegetable-rich diet with decreased endothelial dys-
function (53), including that part of the Mediterranean diet
(54), suggesting that dietary exposure to nrf2 activators
derived from cruciferous vegetables may have be involved.
The functional importance of this finding requires further
evaluation. It is expected that the protective effect of nrf2
activators may be stratified by severity of exposure to
hyperglycemia, with increasing effects in the nondiabetic,
impaired glucose tolerance, and diabetic populations. Hy-
perglycemia alone did not induce ARE-linked gene expres-
sion in HMEC-1 endothelial cells, even when confronted
with damaging insults of oxidative stress and accumula-
tion of dicarbonyls. Physiological activators of nrf2 are
thought to be the lipid peroxidation-derived aldehyde,
4-hydroxynonenal, and J3-isoprostanes (34,55). The meta-
bolic insult of hyperglycemia is of nonlipidic origin. This
may be why the nrf2 system does not respond strongly to
it. There is now evidence that diabetes does induce a weak
nrf2-mediated protective response, for example, in the
high-fat–diet mouse model of type 2 diabetes (56). The
weak response suggests that an effective protection to
prevent vascular disease has not been mounted and,
therefore, provides a clear future opportunity for pharma-
cological intervention. Cruciferous vegetable consumption
and synthetic activators of nrf2 are expected to decrease
the risk of vascular disease in diabetes.
ACKNOWLEDGMENTS
This work has received support from the Juvenile Diabetes
Research Foundation International (New York), the Well-
come Trust (U.K.), and the Biotechnology and Biosciences
Research Council (U.K.).
REFERENCES
1. Stehouwer CDA, Gall MA, Twisk JWR, Knudsen E, Emeis JJ, Parving H-H:
Increased urinary albumin excretion, endothelial dysfunction, and chronic
low-grade inflammation in type 2 diabetes. Diabetes 51:1157–1165, 2002
2. de Jager J, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ, Bouter
LM, Stehouwer CDA: Endothelial dysfunction and low-grade inflammation
explain much of the excess cardiovascular mortality in individuals with
type 2 diabetes: the Hoorn study. Arterioscler Thromb Vasc Biol 26:1086–
1093, 2006
3. Coutinho M, Wang Y, Gerstein HC, Yusuf S: The relationship between
glucose and incident cardiovascular events. Diabetes Care 22:233–240,
1999
4. Meigs JB, O’Donnell CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I,
Nathan DM, Sullivan LM, D’Agostino RB, Wilson PWF: Hemostatic markers
of endothelial dysfunction and risk of incident type 2 diabetes: the
Framingham Offspring Study. Diabetes 55:530–537, 2006
5. Brownlee M: Biochemistry and molecular cell biology of diabetic compli-
cations. Nature 414:813–820, 2001
6. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA,
Hadden D, Turner RC, Holman RR: Association of glycaemic with macro-
vascular and microvascular complications of type 2 diabetes (UKPDS 35):
prospective observational study. BMJ 321:405–412, 2002
7. Du X, Matsumara T, Edelsttein D, Rosetti L, Zsengeller Z, Szabo C,
Brownlee M: Inhibition of GAPDH activity by poly(ADP-ribose) polymer-
ase activates three major pathways of hyperglycemic damage in endothe-
lial cells. J Clin Invest 112:1049–1057, 2003
8. Nyengaard JR, Ido Y, Kilo C, Williamson JR: Interactions between hyper-
glycemia and hypoxia: implications for diabetic retinopathy. Diabetes
53:2931–2938, 2004
9. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ:
Prevention of incipient diabetic nephropathy by high dose thiamine and
benfotiamine. Diabetes 52:2110–2120, 2003
10. Nishikawa T, Edelstein D, Liang Du X, Yamagishi S, Matsumura T, Kaneda
Y, Yorek MA, Beede D, Oates PJ, Hammes H-P, Giardino I, Brownlee M:
Normalizing mitochondrial superoxide production blocks three pathways
of hyperglycaemia damage. Nature 404:787–790, 2000
11. Du X-L, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J,
Brownlee M: Hyperglycemia-induced mitochondrial superoxide overpro-
duction activates the hexosamine pathway and induces plasminogen
activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl
Acad Sci U S A 97:12222–12226, 2000
12. Dobler D, Ahmed N, Song LJ, Eboigbodin KE, Thornalley PJ: Increased
dicarbonyl metabolism in endothelial cells in hyperglycemia induces
anoikis and impairs angiogenesis by RGD and GFOGER motif modifica-
tion. Diabetes 55:1961–1969, 2006
13. Hammes H-P, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J,
Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I,
Brownlee M: Benfotiamine blocks three major pathways of hyperglycemic
ROLE OF ACTIVATION OF nrf2
2816 DIABETES, VOL. 57, OCTOBER 2008
damage and prevents experimental diabetic retinopathy. Nat Med 9:294–
299, 2003
14. Berrone E, Beltramo E, Solimine C, Ape AU, Porta M: Regulation of
intracellular glucose and polyol pathway by thiamine and benfotiamine in
vascular cells cultured in high glucose. J Biol Chem 281:9307–9313, 2006
15. Kobayashi M, Yamamoto M: Molecular mechanisms activating the Nrf2-
Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal
7:385–394, 2005
16. Mathers J, Fraser JA, McMahon M, Saunders RDC, Hayes JD, McLellan LI:
Antioxidant and cytoprotective responses to redox stress. Biochem Soc
Symp 71:157–176, 2004
17. Kwak MK, Itoh K, Yamamoto M, Kensler TW: Enhanced expression of the
transcription factor Nrf2 by cancer chemopreventive agents: role of
antioxidant response element-like sequences in the nrf2 promoter. Mol Cell
Biol 22:2883–2892, 2002
18. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S:
Identification of Nrf2-regulated genes induced by the chemopreventive
agent sulforaphane by oligonucleotide array. Cancer Res 62:5196–5203,
2002
19. Kobayashi, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K,
Yamamoto M: Oxidative stress sensor Keap1 functions as an adaptor for
Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell
Biol 24:7130–7139, 2004
20. Motohashi H, Shavit JA, Igarashi K, Yamamoto M, Engel JD: The world
according to Maf. Nucleic Acids Res 25:2953–2959, 1997
21. Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, Hannink M:
Ubiquitination of Keap1, a BTB-kelch substrate adaptor protein for Cul3,
targets Keap1 for degradation by a proteasome-independent pathway.
J Biol Chem 280:30091–30099, 2005
22. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N,
Katoh Y, Yamamoto M, Talalay P: Direct evidence that sulfhydryl groups of
Keap1 are the sensors regulating induction of phase 2 enzymes that protect
against carcinogens and oxidants. Proc Natl Acad Sci U S A 99:11908–
11913, 2002
23. Lee OH, Jain AK, Papusha V, Jaiswal AK: An auto-regulatory loop between
stress sensors INrf2 and Nrf2 controls their cellular abundance. J Biol
Chem 282:36412–36420, 2007
24. Jain AK, Bloom DA, Jaiswal AK: Nuclear import and export signals in
control of Nrf2. J Biol Chem 280:29158–29168, 2005
25. Pi JB, Bai YS, Reece JM, Williams J, Liu DX, Freeman ML, Fahl WE, Shugar
D, Liu J, Qu W, Collins S, Waalkes MP: Molecular mechanism of human
Nrf2 activation and degradation: role of sequential phosphorylation by
protein kinase CK2. Free Radic Biol Med 42:1797–1806, 2007
26. Jain AK, Jaiswal AK: GSK-3beta acts upstream of Fyn kinase in regulation
of nuclear export and degradation of NF-E2 related factor 2. J Biol Chem
282:16502–16510, 2007
27. Chen XL, Varner SE, Rao AS, Grey JY, Thomas S, Cook CK, Wasserman
MA, Medford RM, Jaiswal AK, Kunsch C: Laminar flow induction of
antioxidant response element-mediated genes in endothelial cells. J Biol
Chem 278:703–711, 2003
28. Song LJ, Morrison JJ, Botting NP, Thornalley PJ: Analysis of glucosino-
lates, isothiocyanates, and amine degradation products in vegetable ex-
tracts and blood plasma by LC-MS/MS. Anal Biochem 347:234–243, 2005
29. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC,
Lawley TJ: HMEC-1: establishment of an immortalized human microvas-
cular endothelial cell line. Invest Dermatol 99:683–690, 1992
30. Snow CM, Senior A, Gerace L: Monoclonal antibodies identify a group of
nuclear pore complex glycoproteins. J Cell Biol 104:1143–1156, 1987
31. Xu K, Thornalley PJ: Studies on the mechanism of the inhibition of human
leukaemia cell growth by dietary isothiocyanates and their cysteine
adducts in vitro. Biochem Pharmacol 60:221–231, 2000
32. Chen XL, Dodd G, Thomas S, Zhang X, Wasserman MA, Rovin BH, Kunsch
C: Activation of Nrf2/ARE pathway protects endothelial cells from oxidant
injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ
Physiol 290:H1862–H1870, 2006
33. Andres E, Loukili NH, Noel E, Kaltenbach G, Abdelgheni MB, Perrin AE,
Noblet-Dick M, Maloisel F, Schlienger JL, Blickle JF: Vitamin B12 (cobal-
amin) deficiency in elderly patients. CMAJ 171:251–259, 2004
34. Ishii T, Itoh K, Ruiz E, Leake DS, Unoki H, Yamamoto M, Mann GE: Role
of Nrf2 in the regulation of CD36 and stress protein expression in murine
macrophages: activation by oxidatively modified LDL and 4-hydroxynon-
enal. Circ Res 94:609–616, 2004
35. Tamareille S, Mignen O, Capiod T, Rucker-Martin C, Feuvray D: High
glucose-induced apoptosis through store-operated calcium entry and cal-
cineurin in human umbilical vein endothelial cells. Cell Calcium 39:47–55,
2006
36. Lee C-K, Klopp RG, Weindruch R, Prolla TA: Gene expression profile of
aging and its retardation by caloric restriction. Science 285:1390–1393,
1999
37. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA: Identification of the
NF-E2-related factor-2-dependent genes conferring protection against ox-
idative stress in primary cortical astrocytes using oligonucleotide microar-
ray analysis. J Biol Chem 278:12029–12038, 2003
38. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, Kensler
TW: Modulation of gene expression by cancer chemopreventive dithiole-
thiones through the Keap1-Nrf2 pathway: identification of novel gene
clusters for cell survival. J Biol Chem 278:8135–8145, 2003
39. Xu K, Thornalley PJ: Involvement of GSH metabolism in the cytotoxicity
of the phenethyl isothiocyanate and its cysteine conjugate to human
leukaemia cells in vitro. Biochem Pharmacol 61:165–177, 2000
40. Bertl E, Bartsch H, Gerhauser C: Inhibition of angiogenesis and endothelial
cell functions are novel sulforaphane-mediated mechanisms in chemopre-
vention. Mol Cancer Ther 5:575–585, 2006
41. Xu K, Thornalley PJ: Signal transduction activated by the cancer chemo-
preventive isothiocyanates: cleavage of BID protein, tyrosine phosphory-
lation and activation of JNK. Br J Cancer 84:670–673, 2001
42. Keum YS, Yu S, Chang PPJ, Yuan X, Kim JH, Xu C, Han J, Agarwal A, Kong
ANT: Mechanism of action of sulforaphane: inhibition of p38 mitogen-
activated protein kinase isoforms contributing to the induction of antiox-
idant response element-mediated heme oxygenase-1 in human hepatoma
HepG2 cells. Cancer Res 66:8804–8813, 2006
43. Cross J, Foss F, Rady J, Macdonald T, Templeton D: The isothiocyanate
class of bioactive nutrients covalently inhibit the MEKK1 protein kinase.
BMC Cancer 7:183, 2007
44. Chen Y-R, Han J, Kori R, Kong ANT, Tan T-H: Phenylethyl isothiocyanate
induces apoptotic signaling via suppressing phosphatase activity against
c-Jun N-terminal kinase. J Biol Chem 277:39334–39342, 2002
45. Yeh CT, Yen GC: Effect of sulforaphane on metallothionein expression and
induction of apoptosis in human hepatoma HepG2 cells. Carcinogenesis
26:2138–2148, 2005
46. Zhang DX, Gutterman DD: Mitochondrial reactive oxygen species-medi-
ated signaling in endothelial cells. Am J Physiol Heart Circ Physiol
292:H2023–H2031, 2007
47. Quagliaro L, Piconi L, Assaloni R, Da Ros R, Szabo C, Ceriello A: Primary
role of superoxide anion generation in the cascade of events leading to
endothelial dysfunction and damage in high glucose treated HUVEC. Nutr
Metab Cardiovasc Dis 17:257–267, 2007
48. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M,
Thaiss F, Stahl RAK, Warnholtz A, Meinertz T, Griendling K, Harison DG,
Fostermann U, Munzel T: Mechanisms underlying endothelial dysfunction
in diabetes mellitus. Circ Res 88:14–22, 2001
49. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R,
Channon KM: Mechanisms of increased vascular superoxide production in
human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric
oxide synthase. Circulation 105:1656–1662, 2002
50. Frisch SM, Screaton RA: Anoikis mechanisms. Curr Opin Cell Biol
13:555–562, 2001
51. Desco MC, Asensi M, Marquez R, Martinez-Valls J, Vento M, Pallardo FV,
Sastre J, Vina J: Xanthine oxidase is involved in free radical production in
type 1 diabetes: protection by allopurinol. Diabetes 51:1118–1124, 2002
52. Chang KC, Paek KS, Kim HJ, Lee YS, Yabe-Nishimura C, Seo HG:
Substrate-induced up-regulation of aldose reductase by methylglyoxal, a
reactive oxoaldehyde elevated in diabetes. Mol Pharmacol 61:1184–1191,
2002
53. Lopez-Garcia E, Schulze MB, Fung TT, Meigs JB, Rifai N, Manson JE, Hu
FB: Major dietary patterns are related to plasma concentrations of markers
of inflammation and endothelial dysfunction. Am J Clin Nutr 80:1029–
1035, 2004
54. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G,
D’Armiento M, D’Andrea F, Giugliano D: Effect of a Mediterranean-style
diet on endothelial dysfunction and markers of vascular inflammation in
the metabolic syndrome: a randomized trial. JAMA 292:1440–1446, 2004
55. Gao L, Wang JK, Sekhar KR, Yin HY, Yared NF, Schneider SN, Sasi S,
Dalton TP, Anderson ME, Chan JY, Morrow JD, Freeman ML: Novel n-3
fatty acid oxidation products activate Nrf2 by destabilizing the association
between Keap1 and Cullin3. J Biol Chem 282:2529–2537, 2007
56. Tanaka Y, Aleksunes LM, Yeager RL, Gyamfi MA, Esterly N, Guo GL,
Klaassen CD: NF-E2-related factor 2 inhibits lipid accumulation and
oxidative stress in mice Fed a high-fat diet. J Pharmacol Exp Ther
325:655–664, 2008
M. XUE AND ASSOCIATES
DIABETES, VOL. 57, OCTOBER 2008 2817
